# UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD

COALITION FOR AFFORDABLE DRUGS VIII, LLC Petitioner,

v.

### THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Patent Owner

\_\_\_\_\_

**Case: IPR2015-01835**Patent No. 8,618,135

PATENT OWNER RESPONSE



#### **TABLE OF CONTENTS**

				<u>Page</u>
I.	INTE	INTRODUCTION		
II.	THE BOARD'S INSTITUTION DECISION			
	A.	Claim Cons	struction	7
	B.	Effective F	iling Date	8
	C.	Person of Ordinary Skill in the Art		9
	D.	D. Grounds of Institution		10
		1.	Stein	10
		2.	Pink Sheet 2004	11
		3.	Chang	12
III.	PAT	ENT OWNE	R'S DECLARANTS	13
IV.	TEC	HNICAL BA	CKGROUND AND STATE OF THE ART	15
	A. Dosi	The Role of Pharmacokinetics and Pharmacodynamics in Drug osing.		
	B. The Impact of Chemical Structure and Therapeutic Classes on the Selection of Dose.			17
	C.	Treatment of	of Hypercholesterolemia and Hyperlipidemia	18
	D.	Statins		19
	E.	Familial Hy	percholesterolemia	20
	F.	MTP Inhibi	tors and the Development of Lomitapide	21
	G.	Dr. Rader's	Invention	23



V.		OUND 1: CLAIMS 1-10 ARE NOT OBVIOUS IN VIEW OF K SHEET 2004 AND CHANG	26			
	A.	There was no motivation to develop lomitapide in March 2005	26			
	B. The Protocol Proposed in Pink Sheet 2004 is Fundamentally Different from the Claimed Invention					
	C. Succe	C. A POSA Would Not Have Had a Reasonable Expectation of Success in Using the Pink Sheet 2004 Protocol with Lomitapide				
VI.	GROUND 2: CLAIMS 1-10 ARE NOT OBVIOUS IN VIEW OF STEIN AND CHANG					
	A.	Stein Is Not Prior Art.	45			
		1. The Stein Presentation is not a "printed publication."	45			
		2. The Stein Slides Are Not a "Printed Publication"	47			
	B. Stein	CFAD Failed to Show Any Motivation to Combine Chang with 49				
	C. Succe	A POSA Would Not Have Had a Reasonable Expectation of ess in Using the Stein Protocol with Lomitapide.	50			
VII.	NOTHING IN THE RECORD POINTS TO THE OBVIOUSNESS OF DEPENDENT CLAIMS 3 AND 4					
	A.	Dependent Claims 3 And 4 Are Patentable52				
	B.	Dependent Claim 8 Is Patentable.	54			
VIII.	OBJECTIVE INDICIA OF NONOBVIOUSNESS SUPPORT THE PATENTABILITY OF THE PATENT CLAIMS					
	A.	The Results of Claimed Dosing Method Are Unexpected	56			
	B.	The Invention Satisfied A Long-Felt, But Unmet, Need	59			
	C	Others Failed to Accomplish What The Claims Achieved	61			



#### IPR2015-01835 Patent Owner Response

	D.	Others in the Field Praised the Claimed Invention	62
		JUXTAPID®, the Commercial Embodiment of the Claimed ntion, is a Commercial Success	62
IX.	THE	IPR PROCESS IS UNCONSTITUTIONAL	64
X	CON	ICLUSION	65



#### **TABLE OF AUTHORITIES**

<u>Cases</u> :	<u>Page</u>
In re Cuozzo Speed Techs., LLC, 793 F.3d 1268 (Fed. Cir. 2015), cert. granted, sub nom. Cuozzo Speed Techs. LLC v. Lee, 136 S.Ct. 890 (2016)	7
In re Hall, 781 F.2d 897 (Fed. Cir. 1986)	46
Intercollegiate Broad. Sys., Inc. v. Copyright Royalty Board et al., 684 F.3d 1332 (D.C. Cir. 2012)	62
<i>In re Klopfenstein</i> , 380 F.3d 1345 (Fed. Cir. 2004)	.10, 44
Mass. Inst. of Tech. v. Harman Int'l Indus., 584 F. Supp. 2d 297 (D. Mass. 2008)	43
MCM Portfolio LLC v. Hewlett-Packard Co., 812 F.3d 1284 (Fed. Cir. 2015)	62
PPC Broadband, Inc. v. Corning Optical Comm. RF LLC, 815 F.3d 734 (Fed. Cir. 2016)	61
PTAB DECISIONS:	
Air Liquide Large Indus. U.S. LP v. Praxair Tech., Inc., IPR2015- 01074, Paper 11 (P.T.A.B. Oct. 26, 2015)	44
Coalition for Affordable Drugs V LLC v. Biogen MA Inc., IPR2015-01136, Paper 23 (P.T.A.B. Sept. 2, 2015)	39
Coalition for Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics, Inc., IPR2015-00817, Paper 12 (P.T.A.B. Aug. 24, 2015)	45
L-3 Commc'n Holdings, Inc. v. Power Survey, LLC, IPR2014-00832, Paper 9 (P.T.A.B. Nov. 14, 2014)	43



## DOCKET

### Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

#### **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

#### **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

#### **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

#### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

